satralizumab

01/01/2020 - "Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial."
01/01/2023 - "Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar."
10/01/2022 - "This analysis evaluated long-term safety findings from the SAkuraSky and SAkuraStar studies with satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD). "
11/28/2019 - "Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder."
11/15/2023 - "Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab."

09/20/2023 - "She underwent a total hip arthroplasty because her right hip pain persisted after satralizumab treatment. "
11/23/2021 - "Some studies of Tocilizumab have shown to reduce pain and fatigue while trials of Satralizumab had non-significant findings. "
01/01/2021 - "Tocilizumab also reduced pain severity in two trials and fatigue scores in one trial, but satralizumab did not significantly improve pain and fatigue. "
03/01/2021 - "This beneficial effect was apparently confined to patients who have anti-AQP4 antibodies and satralizumab did not reduce the rate of pain or fatigue in NMOSD patients."
11/28/2019 - "Among patients with NMOSD, satralizumab added to immunosuppressant treatment led to a lower risk of relapse than placebo but did not differ from placebo in its effect on pain or fatigue. "

01/01/2023 - "Satralizumab was well tolerated in the SAkuraSky and SAkuraStar trials, with infections (e.g. "
05/01/2022 - "In the SAkuraSky study, satralizumab reduced the risk of relapse in patients with NMOSD compared with placebo, with comparable rates of serious adverse events and infections between treatment arms (Yamamura et al., 2019). "
11/15/2023 - "Conclusion Safe satralizumab use requires risk factor assessment to minimize the incidence of severe infections. "
09/20/2023 - "In satralizumab-treated patients, infection cannot be ruled out even without inflammatory findings. "
10/01/2022 - "Similarly, overall rates of infections and serious infections were consistent between the OST and DB periods with satralizumab, with no increase in rates of infections or serious infections over time. "

11/23/2021 - "Some studies of Tocilizumab have shown to reduce pain and fatigue while trials of Satralizumab had non-significant findings. "
01/01/2021 - "Tocilizumab also reduced pain severity in two trials and fatigue scores in one trial, but satralizumab did not significantly improve pain and fatigue. "
03/01/2021 - "This beneficial effect was apparently confined to patients who have anti-AQP4 antibodies and satralizumab did not reduce the rate of pain or fatigue in NMOSD patients."
11/28/2019 - "Among patients with NMOSD, satralizumab added to immunosuppressant treatment led to a lower risk of relapse than placebo but did not differ from placebo in its effect on pain or fatigue. "

11/15/2023 - "Results We identified 6 sepsis cases in NMOSD-satralizumab, of which 5 (83%) developed from urinary tract infections (UTIs). "
11/15/2023 - "In this study, we compared the sepsis characteristics in NMOSD patients administered satralizumab (NMOSD-satralizumab) to those in rheumatoid arthritis patients administered tocilizumab (RA-tocilizumab), another IL-6 inhibitor. "